Last reviewed 2026-04-23 · How we verify

D-2570

D-2570 is a small molecule that targets the PI3K/AKT pathway.

D-2570 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.

At a glance

Mechanism of action

By inhibiting the PI3K/AKT pathway, D-2570 aims to reduce cancer cell proliferation and induce apoptosis. This mechanism is being explored in the treatment of various cancers.

Approved indications

• Metastatic non-small cell lung cancer
• Metastatic breast cancer

Common side effects

• Diarrhea
• Fatigue
• Nausea

Key clinical trials

• A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis (PHASE2)
• Mass Balance Study of [14C] D-2570 (PHASE1)
• A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis. (PHASE3)
• A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) (PHASE2)
• A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis (PHASE2)
• Healthy Volunteer Study (PHASE1)
• Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects (PHASE1)
• Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.